Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Accumulated Expenses for 7 years, with the latest figure at $32.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 61.03% year-over-year to $32.3 million; the trailing twelve-month figure through Mar 2026 stood at $32.3 million (up 61.03% YoY), and the FY2025 full-year result was $33.2 million, up 19.62% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $32.3 million, down from $33.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $37.7 million in Q3 2022, with the low at $19.1 million in Q3 2023.
• Historically, Accumulated Expenses has averaged $27.4 million across 5 years, with a median of $25.0 million in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 64.25% — and 2023, when it plunged 49.42%.
• Xeris Biopharma Holdings' Accumulated Expenses stood at $36.8 million in 2022, then tumbled by 36.09% to $23.5 million in 2023, then rose by 17.89% to $27.7 million in 2024, then increased by 19.62% to $33.2 million in 2025, then dropped by 2.62% to $32.3 million in 2026.
• The last three Accumulated Expenses figures came in at $32.3 million (Q1 2026), $33.2 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.